Your browser doesn't support javascript.
loading
UK Valuation of EQ-5D-5L, a Generic Measure of Health-Related Quality of Life: A Study Protocol.
Rowen, Donna; Mukuria, Clara; Bray, Nathan; Carlton, Jill; Cooper, Sophie; Longworth, Louise; Meads, David; O'Neill, Ciaran; Yang, Yaling.
Affiliation
  • Rowen D; Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, England, UK. Electronic address: d.rowen@sheffield.ac.uk.
  • Mukuria C; Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, England, UK.
  • Bray N; Academy for Health Equity, Prevention and Wellbeing, Bangor University, Bangor, Wales, UK.
  • Carlton J; Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, England, UK.
  • Cooper S; National Institute for Health and Care Excellence, London, England, UK.
  • Longworth L; PHMR Consulting, London, England, UK.
  • Meads D; Academic Unit of Health Economics, University of Leeds, Leeds, England, UK.
  • O'Neill C; Centre for Public Health, Queen's University, Belfast, Northern Ireland; National University of Ireland, Galway, Ireland.
  • Yang Y; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, England, UK.
Value Health ; 26(11): 1625-1635, 2023 11.
Article in En | MEDLINE | ID: mdl-37722593
ABSTRACT

OBJECTIVES:

A high-quality and widely accepted UK EQ-5D-5L value set is urgently required to enable the latest version of EQ-5D scored using recent UK public preferences to inform policy including health technology assessments submitted to the National Institute for Health and Care Excellence. This article outlines the study protocol for the generation of a new EQ-5D-5L UK value set.

METHODS:

Twelve hundred interviews will be undertaken using the composite time trade-off elicitation technique for 102 health states (86 from the international EQ-5D-5L valuation protocol, plus 16 with best predictive performance in an extended design used in the Native American EQ-5D-5L valuation). The sample will be UK adults (age ≥18 years) proportionately representative across England, Wales, Scotland, and Northern Ireland, representative for age, sex, ethnicity, and socioeconomic group, with inclusion of participants with/without health problems. Participants will choose to be interviewed via videoconference (by Zoom) or in-person in a central venue. Data quality will be rigorously assessed.

RESULTS:

The value set will be generated using tobit random effects and heteroscedastic tobit models (with censoring at -1) using all data, excluding time trade-off values highlighted by participants as ones they would reconsider and data from interviewers failing protocol compliance. Quality and acceptance will be achieved by public involvement, regular Steering Group meetings, independent assessment of data quality at 4 time points, and final endorsement of data and analyses.

CONCLUSION:

This study will produce a UK value set for the EQ-5D-5L for use in prospective and retrospective data sets containing EQ-5D-5L data.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Health Status Type of study: Health_technology_assessment / Prognostic_studies Aspects: Patient_preference Limits: Adolescent / Adult / Humans Country/Region as subject: Europa Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Health Status Type of study: Health_technology_assessment / Prognostic_studies Aspects: Patient_preference Limits: Adolescent / Adult / Humans Country/Region as subject: Europa Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2023 Document type: Article